<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2604-1227</journal-id>
<journal-title><![CDATA[Revista mexicana de oftalmología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. mex. oftalmol]]></abbrev-journal-title>
<issn>2604-1227</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Mexicana de Oftalmología A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2604-12272020000500213</article-id>
<article-id pub-id-type="doi">10.24875/rmo.m20000124</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Tratamiento con fármacos antiangiogénicos de la degeneración macular asociada a la edad exudativa: análisis de la función visual a largo plazo en la práctica clínica habitual]]></article-title>
<article-title xml:lang="en"><![CDATA[Treatment of exudative age-related macular degeneration with anti-angiogenic drugs: analysis of long-term visual function in routine clinical practice]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Palazón-Cabanes]]></surname>
<given-names><![CDATA[Ana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Palazón-Cabanes]]></surname>
<given-names><![CDATA[Begoña]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sellés-Navarro]]></surname>
<given-names><![CDATA[Inmaculada]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital General Universitario Reina Sofía Servicio de Oftalmología ]]></institution>
<addr-line><![CDATA[Murcia ]]></addr-line>
<country>España</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Universitario Virgen de la Arrixaca Servicio de Neurología ]]></institution>
<addr-line><![CDATA[Murcia ]]></addr-line>
<country>España</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>10</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>10</month>
<year>2020</year>
</pub-date>
<volume>94</volume>
<numero>5</numero>
<fpage>213</fpage>
<lpage>220</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2604-12272020000500213&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2604-12272020000500213&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2604-12272020000500213&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Objetivo: Analizar los resultados visuales a largo plazo de ojos con degeneración macular asociada a la edad exudativa (DMAE) tratados con inhibidores del factor de crecimiento endotelial en la práctica clínica real.  Método: Estudio retrospectivo que incluye 48 ojos de 44 pacientes con DMAE húmeda, únicamente tratados con fármacos antiangiogénicos. Se analizaron los valores de agudeza visual (AV) tras 6 meses, y tras 1, 3 y 5 años de seguimiento.  Resultados: La AV mejoró de 61.04 a 65.83 letras a los 6 meses, con una pérdida de &#8722;1.14, &#8722;16.88 y &#8722;27.50 letras respecto a la AV inicial a los 1, 3 y 5 años, respectivamente. El porcentaje de ojos con una pérdida &lt; 15 letras fue del 50 y del 33.3% a los 3 y 5 años, respectivamente. Un 14.6% mejoró &#8805; 15 letras a los 3 años y un 12.5% a los 5 años. Los ojos con AV &#8805; 70 letras previo al tratamiento fueron el 41.7%, descendiendo al 22.92% a los 3 años y a 10.42% a los 5 años. El número medio de inyecciones fue 4.81, 2.21, 1.73, 1.17 y 0.9 en el primer, segundo, tercer, cuarto y quinto años de seguimiento, respectivamente, con un número medio de visitas de 7.19, 4.88, 4.02, 3.40 y 2.85, respectivamente. La edad avanzada, la menor AV basal y la pseudofaquia presentaron resultados visuales menos satisfactorios a largo plazo.  Conclusiones: Los resultados visuales de este estudio son inferiores a estudios previos. Sin embargo, el número de inyecciones recibidas fue menor y todos los ojos completaron un seguimiento de 5 años.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Purpose: To analyze the long-term visual outcomes of vascular endothelial growth factor inhibitors in treatment-naïve eyes with neovascular age-related macular degeneration (AMD).  Methods: Retrospective study with 48 eyes of 44 treatment-naïve patients with neovascular AMD treated only with anti-angiogenic. Visual acuity (VA) results were analyzed after 6 months and 1, 3, and 5 years of follow-up.  Results: Mean VA improved from 61.04 to 65.83 letters after 6 months, with a loss of &#8722;1.14, &#8722;16.88 and &#8722;27.50 letters compared to baseline after 1, 3 and 5 years. The proportion of eyes that lost &lt; 15 letters at 3 and 5 years was 50% and 33.3%, respectively. The proportion of eyes with a gain of &gt; 15 letters was 14.6% and 12.5% at 3 and 5 years. The proportion of eyes with a VA &gt; 70 letters was 41.7% at baseline and 22.92% and 10.42% after 3 and 5 years. The mean number of injections received was 4.81, 2.21, 1.73, 1.17 and 0.9 at years 1, 2, 3, 4, and 5, respectively, and the mean number of visits was 7.19, 4.88, 4.02, 3.40, and 2.85. Older age, lower VA at baseline and pseudophakic eyes showed worse long-term visual outcomes.  Conclusions: The visual outcomes of this study are inferior compared to previous studies. Nevertheless, the number of injections received was lower, and all eyes completed a 5-year follow-up.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Degeneración macular asociada a la edad]]></kwd>
<kwd lng="es"><![CDATA[Inhibidores del factor de crecimiento endotelial]]></kwd>
<kwd lng="es"><![CDATA[Agudeza visual]]></kwd>
<kwd lng="es"><![CDATA[Función visual]]></kwd>
<kwd lng="es"><![CDATA[Resultados a largo plazo]]></kwd>
<kwd lng="en"><![CDATA[Age-related macular degeneration]]></kwd>
<kwd lng="en"><![CDATA[Endothelial growth factor inhibitors]]></kwd>
<kwd lng="en"><![CDATA[Visual acuity]]></kwd>
<kwd lng="en"><![CDATA[Visual function]]></kwd>
<kwd lng="en"><![CDATA[Long-term outcomes]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ferris]]></surname>
<given-names><![CDATA[FL]]></given-names>
</name>
<name>
<surname><![CDATA[Wilkinson]]></surname>
<given-names><![CDATA[CP]]></given-names>
</name>
<name>
<surname><![CDATA[Bird]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Chakravarthy]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Chew]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Csaky]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical Classification of Age-related Macular Degeneration]]></article-title>
<source><![CDATA[Ophthalmology]]></source>
<year>2013</year>
<volume>120</volume>
<page-range>844-51</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mordenti]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Cuthbertson]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Ferrara]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Thomsen]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Berleau]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Licko]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration]]></article-title>
<source><![CDATA[Toxicol Pathol]]></source>
<year>1999</year>
<volume>27</volume>
<page-range>536-44</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rosenfield]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Heier]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ranibizumab for neovascular age-related macular degeneration]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2006</year>
<volume>355</volume>
<page-range>1419-31</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Kaiser]]></surname>
<given-names><![CDATA[PK]]></given-names>
</name>
<name>
<surname><![CDATA[Michels]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Soubrane]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Heier]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[RY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ranibizumab versus verteporfin for neovascular age-related macular degeneration]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2006</year>
<volume>355</volume>
<page-range>1432-44</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[The]]></surname>
<given-names><![CDATA[CATT]]></given-names>
</name>
<name>
<surname><![CDATA[Research]]></surname>
<given-names><![CDATA[Group]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ranibizumab and bevacizumab for neovascular age-related macular degeneration]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2011</year>
<volume>364</volume>
<page-range>1897-908</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Regillo]]></surname>
<given-names><![CDATA[CD]]></given-names>
</name>
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Abraham]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Yue]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Ianchulev]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Schneider]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration:PIER Study year 1]]></article-title>
<source><![CDATA[Am J Ophthalmol]]></source>
<year>2008</year>
<volume>145</volume>
<page-range>239-48</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schmidt-Erfurth]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Eldem]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Guymer]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Korobelnik]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Schlingemann]]></surname>
<given-names><![CDATA[RO]]></given-names>
</name>
<name>
<surname><![CDATA[Axer-Siegel]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration:the EXCITE study]]></article-title>
<source><![CDATA[Ophthalmology]]></source>
<year>2011</year>
<volume>118</volume>
<page-range>831-9</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fung]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
<name>
<surname><![CDATA[Lalwani]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
<name>
<surname><![CDATA[Rosenfeld]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Dubovy]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Michels]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Feuer]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An Optical Coherence Tomography-Guided, Variable Dosing Regimen with Intravitreal Ranibizumab (Lucentis) for Neovascular Age-Related Macular Degeneration]]></article-title>
<source><![CDATA[Am J Ophthalmol]]></source>
<year>2007</year>
<volume>143</volume>
<page-range>566-83</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Boyer]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
<name>
<surname><![CDATA[Heier]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Francom]]></surname>
<given-names><![CDATA[SF]]></given-names>
</name>
<name>
<surname><![CDATA[Ianchulev]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Rubio]]></surname>
<given-names><![CDATA[RG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration]]></article-title>
<source><![CDATA[Ophthalmology]]></source>
<year>2009</year>
<volume>116</volume>
<page-range>1731-9</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sadda]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
</person-group>
<source><![CDATA[HORIZON extension trial of ranibizumab [LUCENTIS®] for neovascular agerelated macular degeneration [AMD]:first-year safety and efficacy results]]></source>
<year>2008</year>
<publisher-loc><![CDATA[Scottsdale, USA ]]></publisher-loc>
<publisher-name><![CDATA[Retina Society Annual Meeting]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Holz]]></surname>
<given-names><![CDATA[FG]]></given-names>
</name>
<name>
<surname><![CDATA[Amoaku]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Donate]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Guymer]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
<name>
<surname><![CDATA[Kellner]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Schlingemann]]></surname>
<given-names><![CDATA[RO]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration:the SUSTAIN study]]></article-title>
<source><![CDATA[Ophthalmology]]></source>
<year>2011</year>
<volume>118</volume>
<page-range>663-71</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Spaide]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ranibizumab according to need:a treatment for age-related macular degeneration]]></article-title>
<source><![CDATA[Am J Ophthalmol]]></source>
<year>2007</year>
<volume>143</volume>
<page-range>679-80</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Browning]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Kaiser]]></surname>
<given-names><![CDATA[PK]]></given-names>
</name>
<name>
<surname><![CDATA[Rosenfeld]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Stewart]]></surname>
<given-names><![CDATA[MW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Aflibercept for age-related macular degeneration:a game-changer or quiet addition?]]></article-title>
<source><![CDATA[Am J Ophthalmol]]></source>
<year>2012</year>
<volume>154</volume>
<page-range>222-6</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stewart]]></surname>
<given-names><![CDATA[MW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical and differential utility of VEGF inhibitors in wet age-related macular degeneration:focus on aflibercept]]></article-title>
<source><![CDATA[Clin Ophthalmol]]></source>
<year>2012</year>
<volume>6</volume>
<page-range>1175-186</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rofagha]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Bhisitkul]]></surname>
<given-names><![CDATA[RB]]></given-names>
</name>
<name>
<surname><![CDATA[Boyer]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
<name>
<surname><![CDATA[Sadda]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<collab>SevenUp Study Group</collab>
<article-title xml:lang=""><![CDATA[Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA and HORIZON:a multicenter cohort study (SEVEN-UP)]]></article-title>
<source><![CDATA[Ophthalmology]]></source>
<year>2013</year>
<volume>120</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>2292-9</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<collab>Comparison of Age-Related Macular Degeneration Treatment Trials (CATT) Research Group</collab>
<article-title xml:lang=""><![CDATA[Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration]]></article-title>
<source><![CDATA[Ophthalmology]]></source>
<year>2016</year>
<volume>123</volume>
<page-range>1751-61</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Talks]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Lotery]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Ghanchi]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Sivaprasad]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Johnston]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[First-Year Visual Acuity Outcomes of Providing Aflibercept According to de VIEW Study Protocol for Age-Related Macular Degeneration]]></article-title>
<source><![CDATA[Ophthalmology]]></source>
<year>2016</year>
<volume>123</volume>
<page-range>337-43</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<collab>Committee for de UK Age-Related Macular Degeneration EMR Users Group</collab>
<article-title xml:lang=""><![CDATA[The neovascular age-related macular degeneration database:a multicenter study of 92976 ranibizumab injections:report 1:visual acuity]]></article-title>
<source><![CDATA[Ophthalmology]]></source>
<year>2014</year>
<volume>121</volume>
<page-range>1092-101</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gilles]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Campain]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Barthelmes]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Simpson]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Arnold]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Guymer]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-Term Outcomes of Treatment of Neovascular Age-Related Macular Degeneration]]></article-title>
<source><![CDATA[Ophthalmology]]></source>
<year>2015</year>
<volume>122</volume>
<page-range>1837-45</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gemenetzi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A Systematic Review of the Treat and Extend Treatment Regimen with Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration]]></article-title>
<source><![CDATA[Ophthalmol Ther]]></source>
<year>2017</year>
<volume>6</volume>
<page-range>79-92</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kaiser]]></surname>
<given-names><![CDATA[PK]]></given-names>
</name>
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Hudson]]></surname>
<given-names><![CDATA[HL]]></given-names>
</name>
<name>
<surname><![CDATA[Holz]]></surname>
<given-names><![CDATA[FG]]></given-names>
</name>
<name>
<surname><![CDATA[Shapiro]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ranibizumab for predominantly classic neovascular age-related macular degeneration:subgroup analysis of first-year ANCHOR results]]></article-title>
<source><![CDATA[Am J Ophthalmol]]></source>
<year>2007</year>
<volume>144</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>850-7</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Boyer]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
<name>
<surname><![CDATA[Antoszyk]]></surname>
<given-names><![CDATA[AN]]></given-names>
</name>
<name>
<surname><![CDATA[Awh]]></surname>
<given-names><![CDATA[CC]]></given-names>
</name>
<name>
<surname><![CDATA[Bhisitkul]]></surname>
<given-names><![CDATA[RB]]></given-names>
</name>
<name>
<surname><![CDATA[Shapiro]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Acharya]]></surname>
<given-names><![CDATA[NR]]></given-names>
</name>
</person-group>
<collab>MARINA Study Group</collab>
<article-title xml:lang=""><![CDATA[Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration]]></article-title>
<source><![CDATA[Ophthalmology]]></source>
<year>2007</year>
<volume>114</volume>
<page-range>246-52</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zarranz-Ventura]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Liew]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Johnson]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
<name>
<surname><![CDATA[Xing]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Akerele]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[McKibbin]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<collab>The Neovascular Age-Related Macular Degeneration Database</collab>
<article-title xml:lang=""><![CDATA[Report 2:Incidence, Management, and Visual Outcomes of Second Treated Eyes]]></article-title>
<source><![CDATA[Ophthalmology]]></source>
<year>2014</year>
<volume>121</volume>
<page-range>1966-75</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Eldaly]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Styles]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[First versus second eye intravitreal ranibizumab therapy for wet AMD]]></article-title>
<source><![CDATA[Retina]]></source>
<year>2009</year>
<volume>29</volume>
<page-range>325-8</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Weinberg]]></surname>
<given-names><![CDATA[DV]]></given-names>
</name>
<name>
<surname><![CDATA[Shapiro]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Ehrlich]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ranibizumab Treatment Outcome in Phakic versus Pseudophakic Eyes. An individual Patient Data Analysis of 2 Phase 3 Trials]]></article-title>
<source><![CDATA[Ophthalmology]]></source>
<year>2013</year>
<volume>120</volume>
<page-range>1278-82</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Baek]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Cho]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
<name>
<surname><![CDATA[Cho]]></surname>
<given-names><![CDATA[SW]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[CG]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Intravitreal ranibizumab injection for neovascular age-related macular degeneration in phakic versus pseudophakic eyes]]></article-title>
<source><![CDATA[Retina]]></source>
<year>2013</year>
<volume>33</volume>
<page-range>467-73</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ozkaya]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Alkin]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Yazici]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Demirok]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparison of intravitreal ranibizumab in phakic and pseudophakic neovascular age-related macular degeneration patients with good baseline visual acuity]]></article-title>
<source><![CDATA[Retina]]></source>
<year>2014</year>
<volume>34</volume>
<page-range>853-9</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
